FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer – Jazz Pharmaceuticals

1. FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer  Jazz Pharmaceuticals
2. FDA approves first combination therapy for ES-SCLC maintenance treatment  Investing.com
3. Jazz Pharma’s combination therapy for lung cancer gets US approval  Yahoo Finance
4. FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer  FinancialContent
5. FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC  CancerNetwork

Continue Reading